Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ajh.26123 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CD19: a promising target for systemic sclerosis.
Front Immunol
October 2024
Department of Dermatology, Kanazawa Red Cross Hospital, Japanese Red Cross Society, Kanazawa, Ishikawa, Japan.
Article Synopsis
- * Therapies that deplete B cells, particularly those targeting CD20 like rituximab, have shown promise in alleviating symptoms such as skin and lung issues in SSc patients.
- * Newer treatments focusing on CD19, such as Uplizna, may offer greater efficacy and target a wider range of B cells, but ongoing clinical trials are needed to determine their long-term safety and effectiveness for SSc.
Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus.
Nat Commun
March 2024
Experimental Hematology Unit, Division of Immunology Transplantation and Infectious Diseases (DITID), IRCCS San Raffaele Scientific Institute, Milan, Italy.
Systemic Lupus Erythematosus (SLE) is a progressive disease leading to immune-mediated tissue damage, associated with an alteration of lymphoid organs. Therapeutic strategies involving regulatory T (Treg) lymphocytes, which physiologically quench autoimmunity and support long-term immune tolerance, are considered, as conventional treatment often fails. We describe here a therapeutic strategy based on Tregs overexpressing FoxP3 and harboring anti-CD19 CAR (Fox19CAR-Tregs).
View Article and Find Full Text PDFCD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy.
Blood
May 2024
Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland.
Article Synopsis
- T-cell responses require two signals for effective activation: engagement of T-cell receptors (signal 1) and additional costimulatory signals (signal 2), which T-cell bispecific antibodies (TCBs) can provide by targeting specific antigens and CD3ε.
- The study introduces CD19-CD28, a bispecific CD19-targeted CD28 agonist, designed to enhance the effectiveness of glofitamab, a TCB targeting malignant B cells, by delivering the crucial costimulatory signal 2 needed for stronger T-cell responses.
- Initial results show that combining glofitamab with CD19-CD28 and the 4-1BB agonist significantly improves long
[Long-term follow-up of humanized and murine CD19 CAR-T-cell therapy for B-cell acute lymphoblastic leukemia].
Zhonghua Xue Ye Xue Za Zhi
October 2023
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan 430022, China.
Murine CD19 chimeric antigen receptor T-cell (CAR-T) products have been approved for the treatment of refractory/relapsed (R/R) B-cell acute lymphocytic leukemia (B-ALL) ; moreover, humanized products are also undergoing clinical trials. This study aimed to explore the differences in safety and short- and long-term follow-up efficacy between humanized and murine CD19 CAR-T-cells for treating relapsed and refractory B-ALL. Clinical data of 80 patients with R/R B-ALL treated with CD19-targeted CAR-T-cells at the Union Hospital of Tongji Medical College of Huazhong University of Science and Technology between May 2016 and March 2023 were analyzed, which included 31 patients with murine CAR-T and 49 with humanized products.
View Article and Find Full Text PDFPreclinical study of CD19 detection methods post tafasitamab treatment.
Front Immunol
November 2023
Department of Translational Research, Translational Sciences, MorphoSys AG, Planegg, Germany.
Introduction: Several CD19 targeted antibody-based therapeutics are currently available for patients with diffuse large B-cell lymphoma (DLBCL), including the Fc-modified antibody immunotherapy tafasitamab. This therapeutic landscape warrants the evaluation of potential sequencing approaches. Prior to a subsequent CD19-targeted therapy, CD19 expression on tafasitamab-treated patient biopsy samples may be assessed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!